A Sea Change in MS Treatment��The Potential of Small Molecules

Neurology

A Sea Change in MS Treatment—
The Potential of Small Molecules
A CME Satellite Symposium at the 22nd Annual Meeting of the CMSC

Friday, May 30, 2008
8:00 PM Registration and Dessert
8:30 PM Satellite Symposium
Hyatt Regency Denver at Colorado Convention Center
Capitol Ballroom 5-7

A Sea Change in MS Treatment—The Potential of Small Molecules

Recent advances in understanding the pathogenesis of multiple sclerosis and its relation to treatment, the importance of early intervention, and the use of novel small-molecule therapies are resulting in expanded treatment options and new hope for patients with this debilitating disease. Please join a panel of neurology experts at A Sea Change in MS Treatment—The Potential of Small Molecules to discuss these exciting new developments and the evolving strategies and controversies in optimizing outcomes for patients with multiple sclerosis.

CHAIR
Bruce A. Cohen, MD Professor Davee Department of Neurology Feinberg School of Medicine Northwestern University Chicago, Illinois
FACULTY
Bruce A. C. Cree, MD, PhD, MCR Assistant Professor of Neurology Multiple Sclerosis Center University of California, San Francisco San Francisco, California
Mark S. Freedman, HBSc, MSc, MD Professor of Neurology Department of Medicine University of Ottawa Ottawa, Ontario, Canada
Douglas S. Goodin, MD Professor of Neurology Medical Director Multiple Sclerosis Center University of California, San Francisco San Francisco, California

AGENDA
8:00 PM	Registration and Dessert
8:30 PM	Introduction Bruce A. Cohen, MD
8:35 PM	New Perspectives on the Pathogenesis of MS Douglas S. Goodin, MD
8:50 PM	Goals of Optimal Therapy Bruce A. Cohen, MD
9:05 PM	Current Therapies and Role of Emerging Small-Molecule Therapies in MS – Evolving Strategies Bruce A.C. Cree, MD, PhD, MCR
9:20 PM	Controversies in MS Mark S. Freedman, HBSc, MSc, MD
9:35 PM	Panel Discussion Faculty
9:55 PM	Closing Remarks Bruce A. Cohen, MD

top

TARGET AUDIENCE

This CME activity is designed for neurologists and other clinicians who are involved in the treatment of patients with multiple sclerosis.

ACTIVITY GOAL

The goal of this program is to provide clinicians with state-of-the-science, clinically relevant information concerning the pathophysiology of MS, novel treatments in development, and new strategic approaches that will enable them to optimize therapy for their patients with multiple sclerosis.

LEARNING OBJECTIVES

Assess the etiology, pathophysiology, and course of MS in order to determine appropriate treatment approaches that improve patient outcomes.

Evaluate the inflammatory and neurodegenerative response in MS and potential targets for intervention to select optimal therapies and strategies for the treatment of MS patients.

Apply an understanding of the importance of early treatment intervention and early identification of suboptimal responses in optimizing therapy for patients with MS.

Determine the appropriate use of current and emerging MS agents in treatment strategies for MS patients that improve outcomes through knowledge of their mechanisms of action, efficacy, and safety.

Utilizing expert insights into controversies in the management of MS, implement strategies that improve patient outcomes.

top

CME INFORMATION

Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards of Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians’ Desk Reference (PDR).

Bruce A. Cohen, MD, has served as a consultant for and participated in speakers bureaus of Bayer Pharmaceuticals, Biogen-Idec, EMD-Serono, Pfizer Inc, and Teva Neuroscience; has received consulting fees from Bayer Pharmaceuticals, EMD-Serono, Genentech, Inc, and Teva Neuroscience; has received honoraria directly from Bayer Pharmaceuticals, Biogen-Idec, EMD-Serono, and Teva Neuroscience; and has ownership interest in Abbott Laboratories and CVS-Caremark.

Bruce A.C. Cree, MD, PhD, MCR, has received grant/research support from BioMS Medical, EMD-Serono, and Genentech, Inc; and has participated in the speakers bureaus of Biogen-Idec and Teva Neuroscience.

Mark S. Freedman, HBSc, MSc, MD, has no potential conflicts of interest to disclose.

Douglas S. Goodin, MD, has received grant/research support from Bayer Pharmaceuticals, Biogen-Idec, Novartis Pharmaceuticals Corporation, and Schering-Plough Corporation; has served as a consultant for Bayer Pharmaceuticals, EMD-Serono, and Schering-Plough Corporation; has participated in the speakers bureaus of Bayer Pharmaceuticals, EMD-Serono, Schering-Plough Corporation, and Teva Neuroscience; has received consulting fees from Bayer Pharmaceuticals, EMD-Serono, and Schering-Plough Corporation; and has received honoraria directly from Bayer Pharmaceuticals, EMD-Serono, Schering-Plough Corporation, and Teva Neuroscience.

Peer Reviewer has no significant relationships to disclose.

Projects In Knowledge’s staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the physician caring for the patient.

This independent CME activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

top

1841